PT-141 and melanotan are often confused, but they are very different peptides. Here is how pt 141 melanotan compare in use, dosing, FDA status, and safety.
PT-141 (bremelanotide) and melanotan II are two different peptides that get confused constantly. PT-141 is an FDA-approved prescription drug for low sexual desire in premenopausal women, while melanotan II is an unapproved tanning peptide sold through gray-market websites. Both act on melanocortin receptors, which is why searches for pt 141 melanotan return so many mixed results.
PT-141 is also known by its generic name, bremelanotide, and by the brand name Vyleesi. It is given as a subcutaneous injection and is approved to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It was originally developed as a tanning agent, and researchers noticed increased sexual desire as a side effect during early trials.
What Is Melanotan II?
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone that stimulates melanin production, darkening the skin without UV exposure. It was developed in the 1980s by scientists studying pigmentation.
Melanotan II is not FDA-approved for any human use. It is not a legal prescription drug in the United States, and products sold online as "melanotan" or "MT-2" are unregulated, so the actual peptide content, dose, and sterility of those vials are unknown.
PT-141 vs Melanotan: How They Compare
A direct pt 141 vs melanotan comparison comes down to regulation as much as chemistry. The table below lines up the differences that matter most.
| Feature | PT-141 (bremelanotide) | Melanotan II |
|---|---|---|
| Primary purpose | Treats low sexual desire (HSDD) in premenopausal women | Tanning and skin darkening |
| FDA status | Approved as Vyleesi (2019) | Not approved for any human use |
| Typical dose | 1.75 mg subcutaneous injection | No established safe dose |
| Onset | About 30 to 60 minutes | Days to weeks for a tanning effect |
| Half-life | About 2.7 hours | Not well characterized |
| Common side effects | Nausea, flushing, headache, injection site reactions | Nausea, flushing, darkening of moles |
| Legal to buy | Prescription only | Illegal to sell for human consumption |
Who Uses PT-141, and at What Dose?
Vyleesi is approved for premenopausal women with HSDD. The labeled dose is 1.75 mg injected under the skin of the abdomen or thigh at least 45 minutes before anticipated sexual activity. Users should not exceed one dose in 24 hours or eight doses per month.
Interest in pt-141 for men is high, but the drug is not FDA-approved for male sexual dysfunction. Small studies in men with erectile dysfunction showed some benefit, especially in men who did not respond to PDE5 inhibitors, but the evidence is not strong enough for an approval.
There is no approved dosing for women beyond the 1.75 mg injection. Higher injected doses and nasal products discussed in online forums are not supported by the drug's label.
Nasal Sprays, Timing, and Duration
PT-141 was studied as a nasal spray in early clinical trials, and interest in a pt-141 nasal spray has not faded since. The approved product is an autoinjector, and nasal formulations sold online are compounded or gray-market products that are not FDA-approved.
Do-it-yourself nasal spray recipes circulating on forums involve reconstituting lyophilized powder with sterile water or saline. These carry obvious risks: no sterility testing, no way to verify the identity of the powder, and no reliable dosing.
Timing is fairly predictable. PT-141 is usually injected at least 45 minutes before sexual activity, and most people notice effects within 30 to 60 minutes. As for how long does pt-141 last, the answer is fairly consistent: effects typically fade within two to four hours, in line with a half-life of about 2.7 hours.
Availability: Where to Buy PT-141
In the United States, PT-141 is prescription-only. That means where to buy pt-141 has one legal answer: a licensed pharmacy, with a prescription from a healthcare provider. Sellers that offer it without a prescription are operating outside the law, and the product they ship may be counterfeit or mislabeled.
Melanotan II is a different situation. It has never been approved by the FDA, and the agency has issued repeated warnings about injectable tanning products after reports of serious side effects and hospitalizations.
Side Effects and Safety
The most common PT-141 side effects are nausea, flushing, headache, and injection site reactions. The drug can raise blood pressure temporarily, so it is not recommended for people with uncontrolled hypertension or known cardiovascular disease. Repeated use has been linked to focal hyperpigmentation, including darkening of the gums, face, or breasts.
Melanotan II has no established safety profile. Reported effects include severe nausea, facial flushing, spontaneous erections, and rapid darkening of moles and freckles. Because the peptide acts on melanocytes, researchers have raised concerns about melanoma risk.
None of this is medical advice. Anyone considering PT-141 should talk with a licensed healthcare professional first, and melanotan II cannot be legally prescribed or dispensed for human use in the United States.
The Bottom Line
PT-141 and melanotan II are related molecules with very different legal and clinical statuses. PT-141 has an FDA-approved label, a fixed dose, and a characterized side effect profile. Melanotan II has no approved dose, no quality control, and unresolved questions about long-term cancer risk.
If the goal is treating low sexual desire, PT-141 is the option with clinical evidence and a legal pathway. If the goal is darker skin without UV exposure, the safer choice is a cosmetic self-tanner rather than an unapproved injectable peptide.
Frequently Asked Questions
Is PT-141 the same as melanotan?
No. PT-141 is bremelanotide, an FDA-approved prescription drug for hypoactive sexual desire disorder in premenopausal women. Melanotan II is a separate, unapproved peptide used for tanning. Both are melanocortin receptor agonists, which is why the two are so often confused.
Is PT-141 FDA-approved?
Yes. The FDA approved bremelanotide under the brand name Vyleesi in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is not approved for men, and it is not approved for postmenopausal women.
How long does PT-141 take to work?
PT-141 is injected at least 45 minutes before sexual activity, and most users report effects starting within 30 to 60 minutes. The effects generally last two to four hours. The drug's half-life is about 2.7 hours.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.